
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.
Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.5
22 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.
Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.

28 Listeners

10 Listeners

5 Listeners

10 Listeners

4 Listeners

2 Listeners

4 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

12 Listeners

4 Listeners

3 Listeners

5 Listeners